Clinical trials are research studies designed to discover new ways to treat different cancers, and directly impact the number of new therapies and treatments available to fight cancer. Today’s trials are tomorrow’s standard of cancer care.
Save the date!
Join us for the first annual clinical research conference hosted by Thompson. Learn more and register by clicking here.
Thompson was the first to bring cancer clinical trials to East Tennessee more than 25 years ago. Today, Thompson’s clinical trials department is under the leadership of David Chism, MD and Susan Owenby, RN, CCRP, System Director of Clinical Research. Our oncologists are certified to participate in clinical trials and work with multiple cancer research groups to bring innovative treatments to East Tennessee. In addition, we partner with pharmaceutical companies to give our patients access to new treatments not otherwise available. We offer clinical trials because they often lead to better ways to diagnose, treat, and prevent cancer, allowing people to live healthier and longer lives. Ask your doctor if a clinical trial might be right for you.
Bladder
| Protocol Number | NCT Number | Title | Principal Investigator |
| IMMU 132-13 | A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer | David Chism, MD |
Breast
| Protocol Number | NCT Number | Title | Principal Investigator |
|
A Phase III, Randomized, Double-Blind, Placebo-Controlled clinical trial to evaluate the efficacy and safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at high risk of recurrence following preoperative therapy |
David Chism, MD |
COVID-19
| Protocol Number | NCT Number | Title | Principal Investigator |
| NCICOVID-19 (N-CCAPS) |
A Longitudinal natural History Study |
David Chism, MD |
Gastrointestinal
| Protocol Number | NCT Number | Title | Principal Investigator |
| A021502 | NCT02912559 | Randomized Trial of Standard Chemotherapy alone or combined with Atezolizumab as adjuvant therapy for patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair(ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer) | David Chism, MD |
| NRG-GI005 | NCT04068103 |
Phase II/III Study of Circulating tumor DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
|
David Chism, MD |
Genitourinary
| Protocol Number | NCT Number | Title | Principal Investigator |
| NRG-GU005 | NCT03367702 | Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for localized intermediate risk prostate cancer | Grant Clark, MD |
| NRG-GU009 | NCT04513717 | Parallel Phase III Randomized Trials for High Risk Prostate Cancer evaluating De-Intensification for Lower Genomic risk and intensification of concurrent therapy for Higher Genomic risk with radiation (PREDICT-RT*) *Prostate RNA Expression/Decipher to Individualize Concurrent Therapy with Radiation | David Chism, MD |
Gynecologic
| Protocol Number | NCT Number | Title | Principal Investigator |
| NRG-GY009 | NCT02839707 | A Randomized, Phase 11/111 Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer | Brook Saunders, MD |
Leukemia/Lymphoma
| Protocol Number | NCT Number | Title | Principal Investigator |
| AZA-MDS-006 (CONNECT) | NCT01688011 | The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry | David Chism, MD |
| U2-VEN-207 | NCT03801525 | ULTRA-V: Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL) | David Chism, MD |
Liver
| Protocol Number | NCT Number | Title | Principal Investigator |
| D910DC00001 (EMERALD) | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2) | David Chism, MD |
Lung: Small Cell
| Protocol Number | NCT Number | Title | Principal Investigator |
| NRG-CC003 | NCT02635009 | A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer | Grant Clark, MD |
| NRG-LU005 | NCT03811002 | Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab | Grant Clark, MD |
Lung: Non-Small Cell
| Protocol Number | NCT Number | Title | Principal Investigator |
| D910LC00001 (MeRmaiD1) | NCT04385368 | A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1) | David Chism, MD |
| D910MC00001 (MeRmaiD2) | NCT04642469 |
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2) |
David Chism, MD |
| MK7339-008 | NCT03976362 | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-Small-Cell Lung Cancer (NSCLC) | David Chism, MD |
| MK7902-008 | NCT03976375 | A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic Non- Small Cell Lung Cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (LEAP-008) | David Chism, MD |
| D4194C00008 (OnTRAX) | NCT04381494 | Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab | David Chism, MD |
|
Phase II, Open-Label Safety and Efficacy Study of Telisotuzuumab Vedotin (ABBV-399) in Subjects with previously Treated c-Met+ NSCLC Non-Squamous |
David Chism, MD |
Melanoma
| Protocol Number | NCT Number | Title | Principal Investigator |
| DREAMseq EA6134 |
NCT02224781 | DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial | David Chism, MD |
| EA6141 | NCT02339571 | Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma | David Chism, MD |
Patient Stories
-
This content was written by Shelly Abrams, RN, BSN, Clinical Research Coordinator Can Mobile Devices Identify Post-Treatment Problems Early? ON TRAX – Evaluating a mobile technology monitoring device used in patients with inoperable Stage 3 Lung Cancer Lung cancer is one of the leading causes of cancer deaths in men and women worldwide. People […]
-
This content was written by Jessica Severt RN, BSN, Clinical Research Nurse Coordinator at Thompson Cancer Survival Center. Clinical trials are how we discover new and superior treatments, better ways to prevent side effects, and improve survival rates for cancer patients. According to research, only approximately 3-5% of adult cancer patients participate in a clinical […]